Ikarian Capital’s PDS Biotechnology PDSB Stock Holding History

Ikarian Capital’s Portfolio PDSB Stock Details PDSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,672	Closed	-$22K	–	187
2022 Q1	$22K	Buy	3,672 +177	+5%	+$1.1K	﹤0.01%	190
2021 Q4	$28K	Buy	+3,495	New	+$37.6K	﹤0.01%	178
2021 Q2	–	Sell	-383,373	Closed	-$1.75M	–	263
2021 Q1	$1.75M	Buy	+383,373	New	+$1.54M	0.06%	212

Other funds holding PDSB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ikarian Capital's PDSB Position: Q2 2022 in Review

Ikarian Capital sold out of PDS Biotechnology (PDSB) in Q2 2022, closing a stake of 3,672 shares — an estimated $22K sold.

Ikarian Capital first reported a position in PDSB in Q1 2021 and held it in 3 quarters. The position peaked at $1.75M in Q1 2021. 51 funds tracked by Wall St. Rank hold PDSB as of Q2 2022.

Ikarian Capital reported no remaining PDS Biotechnology position as of Q2 2022 after selling out during the quarter.
Ikarian Capital sold 3,672 PDS Biotechnology shares in Q2 2022, an estimated $22K.
Ikarian Capital first reported a position in PDS Biotechnology in Q1 2021 and held it in 3 quarters.
Ikarian Capital's PDS Biotechnology position peaked at $1.75M in Q1 2021.
51 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.